2026-06-23T04:34:16Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/712832024-09-27T18:03:32Zcom_20.500.14352_14col_20.500.14352_15

Benito Villalvilla, Cristina Pérez Diego, Mario Angelina Querencias, Alba Kisand, Kai Rebane, Ana Subiza, José Luis Palomares Gracia, Óscar 2023-06-22T10:40:20Z 2023-06-22T10:40:20Z 2022-06-18 0091-6749 10.1016/j.jaci.2021.06.012 https://hdl.handle.net/20.500.14352/71283 https://doi.org/10.1016/j.jaci.2021.06.012 Allergoid–mannan conjugates are novel vaccines for allergen-specific immunotherapy being currently assayed in phase 2 clinical trials. Allergoid–mannan conjugates target dendritic cells (DCs) and generate functional forkhead box P3 (FOXP3)-positive Treg cells, but their capacity to reprogram monocyte differentiation remains unknown. eng https://creativecommons.org/licenses/by-nc-nd/3.0/es/ open access Atribución-NoComercial-SinDerivadas 3.0 España Allergoid–mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring journal article